Portal de Periódicos da CAPES

A review of the assessment of dyskinesias

1999; Wiley; Volume: 14; Issue: 5 Linguagem: Inglês

10.1002/1531-8257(199909)14

1531-8257

Jorrit I. Hoff, Bob J. van Hilten, Raymund A.C. Roos,

Neurological disorders and treatments

Movement DisordersVolume 14, Issue 5 p. 737-743 Review A review of the assessment of dyskinesias Jorrit I. Hoff MD, Jorrit I. Hoff MD Department of Neurology, Leiden University Medical Center, Leiden, The NetherlandsSearch for more papers by this authorBob J. van Hilten MD, PhD, Corresponding Author Bob J. van Hilten MD, PhD Department of Neurology, Leiden University Medical Center, Leiden, The NetherlandsDepartment of Neurology K5-Q, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The NetherlandsSearch for more papers by this authorRaymund A. C. Roos MD, PhD, Raymund A. C. Roos MD, PhD Department of Neurology, Leiden University Medical Center, Leiden, The NetherlandsSearch for more papers by this author Jorrit I. Hoff MD, Jorrit I. Hoff MD Department of Neurology, Leiden University Medical Center, Leiden, The NetherlandsSearch for more papers by this authorBob J. van Hilten MD, PhD, Corresponding Author Bob J. van Hilten MD, PhD Department of Neurology, Leiden University Medical Center, Leiden, The NetherlandsDepartment of Neurology K5-Q, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The NetherlandsSearch for more papers by this authorRaymund A. C. Roos MD, PhD, Raymund A. C. Roos MD, PhD Department of Neurology, Leiden University Medical Center, Leiden, The NetherlandsSearch for more papers by this author First published: 16 January 2001 https://doi.org/10.1002/1531-8257(199909)14:5 3.0.CO;2-ACitations: 23AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract Dyskinesias are most prevalent in patients with Huntington's disease (HD), patients with Parkinson's disease (PD) who have received chronic levodopa therapy, and in patients who have been treated with neuroleptics (tardive dyskinesia [TD]). Recent therapeutic developments have fueled a growing interest in the clinimetrics of dyskinesias. For dyskinesias in HD, few rating scales are available, but data on validity, reliability, and responsiveness are scarce. Only the interrater reliability of facial dyskinesias has been evaluated and found to be low. Many subjective rating scales for dyskinesias in PD exist, but only the Dyskinesia Rating Scale has undergone sufficient clinimetric evaluation. For TD, numerous rating scales are available, many of them with ample data on reliability and validity. Objective assessment of dyskinesias has been attempted with a number of techniques. All these methods require a laboratory setting, rendering them susceptible to influence of stress. Moreover, they provide only a momentary assessment of dyskinesia severity and fail to take into account diurnal fluctuations. In view of the methodologic shortcomings in the assessment of dyskinesias, more effort needs to be put into strengthening currently available modes of assessment or designing new ones. In the future ambulatory accelerometry might prove to be of value in this field. REFERENCES 1Marsden CD, Parked JD, Quin NM. Fluctuations of disability in Parkinson's disease—clinical aspects. In: CD Marsden, S Fahn, eds. Movement Disorders. London: Butterworths Scientific, 1982: 96–122. 2Soares KVS, McGrath JJ. Anticholinergic medication for neuroleptic induced tardive dyskinesia. In: Adams CE, Duggan L, de Jesus Mari J, White P, eds. Schizophrenia Module of the Cochrane Database of Systematic Reviews [updated June 2, 1997]. Available in The Cochrane Library [database on disk and CD-ROM]. The Cochrane Collaboration, Issue 3. Oxford: Update Software, 1997. Updated quarterly. 3van Vugt JP, Siesling S, Vergeer M, van derVelde EA, Roos RA. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry 1997; 63: 35–39. 4Factor SA, Friedman JH. The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997; 12: 483–496. 5Lang AE, Lozano AM, Montgomery E, Duff J, Tasker R, Hutchinson W. Posteroventral medial pallidotomy in advanced Parkinson's disease. N Engl J Med 1997; 337: 1036–1042. 6Krack P, Limousin P,Benabid AL, Pollak P. Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson's disease. Lancet 1997; 350: 1676. 7Wang Y, Turnbull I, Calne S, Stoessl AJ, Calne DB. Pallidotomy for tardive dyskinesia. Lancet 1997; 347: 777–778. 8Calne DB. Involuntary movements: an overview. In: AB Joseph, RR Young, eds. Movement Disorders in Neurology and Neuropsychiatry. Boston, MA: Blackwell Scientific Publications, 1992: 1–2. 9Siesling S, van Vugt JPP, Zwinderman AH, Kieburtz K, Roos RAC. Unified Huntington's Disease Rating Scale: a follow-up. Mov Disord 1998; 13: 915–919. 10Marconi R, Lefebvre-Caparros D, Bonnet A, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesias in Parkinson's disease: phenomenology and pathophysiology. Mov Disord 1994; 9: 2–12. 11Brown KW, White T. The influence of topography on the cognitive and psychopathological effects of tardive dyskinesia. Am J Psychiatry 1992; 149: 1385–1389. 12Gureje O. Topographic subtypes of tardive dyskinesia in schizophrenic patients aged less than 60 years: relationship to demographic, clinical, treatment, and neuropsychological variables. J Neurol Neurosurg Psychiatry 1988; 51: 1525–1530. 13Wood PHN. Appreciating the consequences of disease: the international classification of impairments, disabilities, and handicaps. WHO Chronicle 1980; 34: 376–380. 14Hobart JC, Lamping DL, Thompson AJ. Evaluating neurological outcome measures: the bare essentials. J Neurol Neurosurg Psychiatry 1996; 60: 127–130. 15Golbe LI, Pae J. Validity of a mailed epidemiological questionnaire and physical self-assessment in Parkinson's disease. Mov Disord 1988; 3: 245–254. 16Shoulson I, Goldblatt D, Charlton M, Joynt RJ. Huntington's disease: treatment with muscimol, a GABA-mimetic drug. Ann Neurol 1978; 4: 279–284. 17Marsden CD, Schachter M. Assessment of extrapyramidal disorders. Br J Clin Pharmacol 1981; 11: 129–151. 18 Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996; 11: 136–142. 19de Boo G, Tibben A, Hermans J, Maat A, Roos RAC. Subtle involuntary movements are not reliable indicators of incipient Huntington's disease. Mov Disord 1998; 13: 96–99. 20Fahn S, Elton RL. The Unified Parkinson's Disease Rating Scale. In: S Fahn, CD Marsden, DB Calne, M Goldstein, eds. Recent Developments in Parkinson's Disease, vol 2. Florham Park, NJ: Macmillan Healthcare Information, 1987: 153–163. 21Larsen TA, Calne S, Calne DB. Assessment of Parkinson's disease. Clin Neuropharmacol 1984; 7: 165–169. 22Montgomery GK, Reynolds NC Jr, Warren RM. Qualitative assessment of Parkinson's disease: study of reliability and data reduction with an abbreviated Columbia scale. Clin Neuropharmacol 1985; 8: 83–92. 23Kurlan R, Rubin AJ, Miller C, Rivera-Calimlim L, Clarke C, Shoulson I. Duodenal delivery of levodopa for on–off fluctuations in parkinsonism: preliminary observations. Ann Neurol 1986; 20: 262–265. 24Lieberman A, Dziatolowski M, Gopinathan G, Kupersmith M, Neophytides A, Korein J. In: M Goldstein, DB Calne, A Lieberman, MD Thorner, eds. Ergot Compounds and Brain Function. New York, NY: Raven Press, 1980: 277–286. 25Mouradian MM, Juncos JL, Fabbrini G, Schlegel J,Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part II. Ann Neurol 1988; 24: 372–378. 26Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The 'on–off' phenomenon in Parkinson's disease. N Engl J Med 1984; 310: 483–488. 27Teychenne PF, Pfeiffer RF, Bern SM, McInturff D, Calne DB. Comparison between lergotrile and bromocriptine in parkinsonism. Ann Neurol 1978; 3: 319–324. 28Langston JW, Widner H, Goetz CG, et al. Core Assessment Program for Intracerebral Transplantation (CAPIT). Mov Disord 1992; 7: 2–13. 29Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intra-rater reliability assessment. Mov Disord 1994; 9: 390–394. 30Caligiuri MP. Instrumental measurement of tardive dyskinesia. In: R Yassa, NPV Nair, DP Jeste, eds. Neuroleptic Induced Movement Disorders: A Comprehensive Survey. New York, NY: Cambridge University Press, 1997: 241–256. 31Simpson GM, Singh H. Tardive dyskinesia rating scales. L'Encephale 1988; 14: 175–182. 32Gardos G, Cole JO, La Brie R. The assessment of tardive dyskinesia. Arch Gen Psychiatry 1977; 34: 1206–1212. 33May PRA, Lee MA, Bacon RC. Quantitative assessment of neuroleptic-induced extrapyramidal symptoms: clinical and non-clinical approaches. Clin Neuropharmacol 1983; 6(suppl 1): S35–S51. 34Bostrom AC. Assessment scales for tardive dyskinesia. J Psychosoc Nurs Ment Health Serv 1988; 26: 9–12. 35 AIMS. In: W Guy, ed. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: United States Department of Health, Education, and Welfare, 1976: 534–537. 36Lane RD, Glazer WM, Hansen TE, Berman WH, Kramer SI. Assessment of tardive dyskinesia using the abnormal involuntary movement scale. J Nerv Ment Dis 1985; 173: 353–357. 37Simpson GM, Lee JH, Zoubok B, Gardos G. A rating scale for tardive dyskinesia. Psychopharmacology 1979; 64: 171–179. 38Sprague RL, Kalachnik JE, Breuning SE, et al. The dyskinesia identification system—Coldwater (DIS—Co): a tardive dyskinesia rating scale for the developmentally disabled. Psychopharmacol Bull 1984; 20: 328–338. 39Sprague RL, Kalachnik JE. Reliability, validity, and a total cutoff score for the dyskinesia identification system: condensed user scale (DISCUS) with mentally ill and mentally retarded populations. Psychopharmacol Bull 1991; 27: 51–58. 40Smith RC, Allen R, Gordon J, Wolff J. A rating scale for tardive dyskinesia and parkinsonian symptoms. Psychopharmacol Bull 1983; 19: 266–276. 41Barnes TRE, Trauer T. Reliability and validity of a tardive dyskinesia videotape rating technique. Br J Psychiatry 1982; 140: 508–515. 42Richardson MA, Craig TJ, Branchey MH. Intra-patient variability in the measurement of tardive dyskinesia. Psychopharmacology 1982; 76: 269–272. 43Yanagisawa N, Nezu A. Pathophysiology of involuntary movements in Parkinson's disease. Eur Neurol 1987; 26(suppl 1): 30–40. 44Yanagisawa N. EMG characteristics of involuntary movements. In: Bruyn GW, Buruma OJS, Roos RAC, eds. Dyskinesia. Proceedings of a Boerhaave Course and Japanese–Dutch workshop. Uden: Sandoz BV, 1984. 45Bathien N, Rondot P, Koutlidis RM. Neurophysiologie clinique des dyskinesies tardives post-neuroleptiques et des dyskinesies dopa-induites de la maladie de Parkinson. J Physiol (Paris) 1981; 77: 131–141. 46Bathien N, Koutlidis RM, Rondot P. EMG patterns in abnormal involuntary movements induced by neuroleptics. J Neurol Neurosurg Psychiatry 1984; 47: 1002–1008. 47Marsden CD, Obeso JA, Rothwell JC. Clinical neurophysiology of muscle jerks: myoclonus, chorea, and tics. In: JE Desmedt, ed. Motor Control Mechanisms in Health and Disease. New York, NY: Raven Press, 1983: 865–881 ( Adv Neurol, vol 39). 48Tan BK, Mastebroek HAK, Zaagman WH. Huntington's chorea. A random process. Clin Neurol Neurosurg 1976; 79: 215–221. 49Yanagisawa N. The spectrum of motor disorders in Huntington's disease. Clin Neurol Neurosurg 1992; 94(suppl): S182–S184. 50Hallett M. Analysis of abnormal voluntary and involuntary movements with surface electromyography. In: JE Desmedt, ed. Motor Control Mechanisms in Health and Disease. New York, NY: Raven Press, 1983: 907–914 (Adv Neurol, vol 39). 51Haines J, Sainsbury P. Ultrasound system for measuring patients' activity and disorders of movement. Lancet 1972; 2: 802–803. 52Resek G, Haines J, Sainsbury P. An ultrasound technique for the assessment of tardive dyskinesia. Br J Psychiatry 1981; 138: 474–478. 53Sainsbury P, Wood E. Measuring gesture: its cultural and clinical correlates. Psychol Med 1977; 2: 63–72. 54McCleland HA, Fairbairn AF, McDonald M, Nicholas TRM, Cox GA. The evaluation of an ultrasound detector (UD) in the measurement of oro-facial dyskinesia. Int Clin Psychopharmacol 1987; 2: 159–164. 55Symington GR, Leonard DP, Shannon PJ, Vajda FJE. Sodium valproate in Huntington's disease. Am J Psychiatry 1978; 135: 352–354. 56Leonard DP, Kidson, MA, Shannon PJ, Brown J. Double-blind trial of lithium carbonate and haloperidol in Huntington's chorea. Lancet 1974; 2: 1208–1209. 57Bartzokis G, Wirshing WC, Hill MA, Cummings JL, Altshuler L, May PRA. Comparisons of electromechanical measures and observer ratings of tardive dyskinesia. Psychiatry Res 1989; 27: 193–198. 58Wirshing WC, Cummings JL, Dencker SJ, May PRA. Electromechanical characteristics of tardive dyskinesia. J Neuropsychiatry Clin Neurosci 1991; 3: 10–17. 59Buruma OJS, Kemp B, Roos RAC, Franzen JM, Veldevander EA. Quantification of choreatic movements by Doppler radar. Acta Neurol Scand 1982; 66: 363–368. 60Falek A. Preclinical detection of Huntington's chorea. In: Barbeau A, Brunette J-R, eds. Progress in Neuro-genetics. Proceedings of the Second International Congress of Neurogenetics. Amsterdam: Exerpta Medica Foundation, 1976. 61Fann WE, Stafford JR, Malone RL, Frost JD, Richman BW. Clinical research techniques in tardive dyskinesia. Am J Psychiatry 1977; 34: 759–762. 62Buruma OJS, Roos RAC, Furnee EH, Antwerpen van G. Assessment of dyskinesia. In: GW Bruyn, OJS Buruma, RAC Roos, eds. Dyskinesia. Leiden: Boerhaave, 1984. 63Denney D, Casey D. An objective method for measuring dyskinetic movements in tardive dyskinesia. Electroencephalogr Clin Neurophysiol 1975; 38: 645–646. 64Chien CP, Jung K, Ross-Townsend A, Stearns B. The measurement of persistent dyskinesia by piezoelectric recording and clinical rating scales. Psychopharmacol Bull 1977; 13: 34–36. 65Nilsson FM, Hansen BL, Buchel C, Gattaz WF, Gerlach J. Digital movement analysis, a new objective method of measuring tardive dyskinesia and drug-induced parkinsonian tremor: acceptability, reliability and validity. Eur Arch Psychiatry Clin Neurosci 1996; 246: 71–77. 66Klawans HL, Rubowitz R. Effect of cholinergic and anticholinergic agents on tardive dyskinesia. J Neurol Neurosurg Psychiatry 1974; 27: 941–947. 67Hagell P, Widner H. Clinical rating of dyskinesias in Parkinson's disease: use and reliability of a new rating scale. Mov Disord 1999; 14: 448–455. Citing Literature Volume14, Issue5September 1999Pages 737-743 ReferencesRelatedInformation